Cite
MLA Citation
Sibylle Loibl et al.. “Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.” Lancet oncology, vol. 19, no. 4, 2018, pp. 497–509. http://access.bl.uk/ark:/81055/vdc_100059052705.0x00000f